Individualization of 5-Fluorouracil in the Treatment of Colorectal Cancer

Alnaim, Lamya

doi:https://doi.org/10.3814/2010/352491

SRX Pharmacology

On this page

Abstract References Copyright Related Articles

Review Article | Open Access

Volume 2010 | Article ID 352491 | https://doi.org/10.3814/2010/352491

Individualization of 5-Fluorouracil in the Treatment of Colorectal Cancer

Lamya Alnaim¹

Received14 Oct 2009

Accepted24 Nov 2009

Published23 Feb 2010

Abstract

Chemotherapeutic agents are generally characterized by a large inter-individual pharmacokinetic variability. The balance of efficacy and toxicity is critical and the imbalance can have devastating effects on patients. Standard dosing methods are inadequate in optimizing systemic exposure .Therapeutic drug monitoring (TDM) has the potential to improve the clinical use of chemotherapy agents. TDM has been successfully applied to optimize a few anticancer treatments including carboplatin, methotrexate, and 6-mercaptopurine. 5-Flurouracil (5-FU) is considered the backbone in treatments of advanced CRC. Toxic side effects remain a significant problem despite increased safety of newer regimens. Molecular mechanisms that control DPD-activity are complex and have not been fully elucidated and cannot be used effectively to individualize Fluorouracil dosing as there is no established standard genetic test for DPD deficiency. Current phenotypic methods to measure DPD-activity are cumbersome. A reliable relationship between DPD genotype and 5-FU toxicity phenotype has not been established. Standard dosing of 5FU is by body surface area (BSA). Low correlation exists between exposure and BSA. A better predictor of total exposure is the area under the curve (AUC). Toxicity and efficacy have been correlated to AUC with target of 24-30 (mg.h/l). The therapeutic window is very narrow and difficult to attain by clinical follow-up alone. TDM has been shown effective in adjusting the dose based on AUC.

References

W. E. Evans and M. V. Relling, “Clinical pharmacokinetics-pharmacodynamics of anticancer drugs,” Clinical Pharmacokinetics, vol. 16, no. 6, pp. 327–336, 1989.
View at: Google Scholar
E. Masson and W. C. Zamboni, “Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes,” Clinical Pharmacokinetics, vol. 32, no. 4, pp. 324–343, 1997.
View at: Google Scholar
A. J. Galpin and W. E. Evans, “Therapeutic drug monitoring in cancer management,” Clinical Chemistry, vol. 39, no. 11, pp. 2419–2430, 1993.
View at: Google Scholar
V. T. DeVita, “Principles of cancer management: chemotherapy,” in Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, and S. A. Rosenberg, Eds., pp. 333–347, Lippincott, Philadelphia, Pa, USA, 5th edition, 1997.
View at: Google Scholar
M. J. Moore and C. Erlichman, “Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy,” Clinical Pharmacokinetics, vol. 13, no. 4, pp. 205–227, 1987.
View at: Google Scholar
J. H. Rodman and W. E. Evans, “Targeted systemic exposure for pediatric cancer therapy,” in Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, D. D'Argenio, Ed., pp. 177–183, Plenum Press, New York, NY, USA, 1991.
View at: Google Scholar
M. W. Linder, R. A. Prough, and R. Valdes, “Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency,” Clinical Chemistry, vol. 43, no. 2, pp. 254–266, 1997.
View at: Google Scholar
M. T. Zühlsdorf, “Relevance of pheno- and genotyping in clinical drug development,” International Journal of Clinical Pharmacology and Therapeutics, vol. 36, no. 11, pp. 607–612, 1998.
View at: Google Scholar
E. Gamelin, M. Boisdron-Celle, V. Guérin-Meyer et al., “Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1105–1110, 1999.
View at: Google Scholar
P. Houyau, C. Gay, E. Chatelut, P. Canal, H. Roche, and G. Milano, “Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency,” Journal of the National Cancer Institute, vol. 85, no. 19, pp. 1602–1603, 1993.
View at: Google Scholar
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007.
View at: Publisher Site | Google Scholar
M. Quinn, P. Babb, A. Brock, L. Kirby, and J. Jones, Cancer Trends in England and Wales 1950–1999, The Stationery Office, London, UK, 2008.
D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
View at: Google Scholar
T. Asano and R. S. McLeod, “Dietary fibre for the prevention of colorectal adenomas and carcinomas,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003430, 2002.
View at: Google Scholar
K. B. Michels, E. Giovannucci, A. T. Chan, R. Singhania, C. S. Fuchs, and W. C. Willett, “Fruit and vegetable consumption and colorectal adenomas in the nurses' health study,” Cancer Research, vol. 66, no. 7, pp. 3942–3953, 2006.
View at: Publisher Site | Google Scholar
T. Norat, S. Bingham, P. Ferrari et al., “Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition,” Journal of the National Cancer Institute, vol. 97, no. 12, pp. 906–916, 2005.
View at: Publisher Site | Google Scholar
Y.-I. Kim, “Folate and colorectal cancer: an evidence-based critical review,” Molecular Nutrition and Food Research, vol. 51, no. 3, pp. 267–292, 2007.
View at: Publisher Site | Google Scholar
C. Dubé, A. Rostom, G. Lewin et al., “The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 146, no. 5, pp. 365–375, 2007.
View at: Google Scholar
A. Rostom, C. Dubé, G. Lewin et al., “Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 146, no. 5, pp. 376–389, 2007.
View at: Google Scholar
J. A. Chan, J. A. Meyerhardt, A. T. Chan, E. L. Giovannucci, G. A. Colditz, and C. S. Fuchs, “Hormone replacement therapy and survival after colorectal cancer diagnosis,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5680–5686, 2006.
View at: Publisher Site | Google Scholar
T. Pischon, P. H. Lahmann, H. Boeing et al., “Body size and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC),” Journal of the National Cancer Institute, vol. 98, no. 13, pp. 920–931, 2006.
View at: Publisher Site | Google Scholar
K. F. Adams, M. F. Leitzmann, D. Albanes et al., “Body mass and colorectal cancer risk in the NIH-AARP cohort,” American Journal of Epidemiology, vol. 166, no. 1, pp. 36–45, 2007.
View at: Publisher Site | Google Scholar
L. A. G. Ries, D. Melbert, M. Krapcho et al., Eds., SEER Cancer Statistics Review, 1975-2005, National Cancer Institute, Bethesda, Md, USA, 2008, http://seer.cancer.gov/csr/1975_2005/.
J. Skibber, B. Minsky, and P. Hoff, “Cancer of the colon,” in Cancer: Principles and Practice of Oncology, V. DeVita, S. Hellman, and S. Rosenberg, Eds., pp. 1216–1270, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001.
View at: Google Scholar
J. Skibber, P. Hoff, and B. Minsky, “Cancer of the rectum,” in Cancer: Principles and Practice of Oncology, V. DeVita, S. Hellman, and S. Rosenberg, Eds., pp. 1271–1318, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001.
View at: Google Scholar
M. Buyse, A. Zeleniuch-Jacquotte, and T. C. Chalmers, “Adjuvant therapy of colorectal cancer. Why we still don't know,” Journal of the American Medical Association, vol. 259, no. 24, pp. 3571–3578, 1988.
View at: Google Scholar
R. Labianca, S. Marsoni, G. Pancera et al., “Efficacy of adjuvant fluorouracil and folinic acid in colon cancer,” The Lancet, vol. 345, no. 8955, pp. 938–944, 1995.
View at: Publisher Site | Google Scholar
N. Wolmark, H. Rockette, B. Fisher et al., “The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 1879–1887, 1993.
View at: Google Scholar
M. J. O'Connell, J. A. Mailliard, M. J. Kahn et al., “Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 246–250, 1997.
View at: Google Scholar
A. de Gramont, J.-F. Bosset, C. Milan et al., “Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 808–815, 1997.
View at: Google Scholar
P. Piedbois, “Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3537–3541, 1998.
View at: Google Scholar
A. B. P. van Kuilenburg, J. Haasjes, D. J. Richel et al., “Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene,” Clinical Cancer Research, vol. 6, no. 12, pp. 4705–4712, 2000.
View at: Google Scholar
R. Meinsma, P. Fernandez-Salguero, A. B. P. van Kuilenburg, A. H. van Gennip, and F. J. Gonzalez, “Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea,” DNA and Cell Biology, vol. 14, no. 1, pp. 1–6, 1995.
View at: Google Scholar
S. Takai, P. Fernandez-Salguero, S. Kimura, F. J. Gonzalez, and K. Yamada, “Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization,” Genomics, vol. 24, no. 3, pp. 613–614, 1994.
View at: Publisher Site | Google Scholar
N. Albin, M. R. Jonhson, H. Shahinian et al., “Initial characterization of the molecular defect in human dihydropyrimidine dehydrogenase deficiency,” Proceedings of the American Association for Cancer Research, vol. 36, p. 211A, 1995.
View at: Google Scholar
“The NCCN Colon Cancer Clinical Practice Guidelines in Oncology (Version 2.2009),” National Comprehensive Cancer Network, Inc. 2009, http://www.nccn.org.
View at: Google Scholar
S. T. Pullarkat, J. Stoehlmacher, V. Ghaderi et al., “Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy,” The Pharmacogenomics Journal, vol. 1, no. 1, pp. 65–70, 2001.
View at: Google Scholar
S. Marsh, J. A. McKay, J. Cassidy, and H. L. McLeod, “Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer,” International Journal of Oncology, vol. 19, no. 2, pp. 383–386, 2001.
View at: Google Scholar
G. Bocci, C. Barbara, F. Vannozzi et al., “A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity,” Clinical Pharmacology and Therapeutics, vol. 80, no. 4, pp. 384–395, 2006.
View at: Publisher Site | Google Scholar
G. Bocci, R. Danesi, A. Di Paolo et al., “Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients,” Clinical Cancer Research, vol. 6, no. 8, pp. 3032–3037, 2000.
View at: Google Scholar
G. K. McEvoy, ed., “Fluorouracil,” in AHFS Drug Information, pp. 1020–1024, American Society of Health-System Pharmacists, Bethesda, Md, USA, 2005.
View at: Google Scholar
H. Ezzeldin and R. Diasio, “Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration,” Clinical Colorectal Cancer, vol. 4, no. 3, pp. 181–189, 2004.
View at: Publisher Site | Google Scholar
E. S. R. Collie-Duguid, M. C. Etienne, G. Milano, and H. L. McLeod, “Known variant DPYD alleles do not explain DPD deficiency in cancer patients,” Pharmacogenetics, vol. 10, no. 3, pp. 217–223, 2000.
View at: Google Scholar
A. B. P. Van Kuilenburg, R. Meinsma, L. Zoetekouw, and A. H. Van Gennip, “High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity,” Pharmacogenetics, vol. 12, no. 7, pp. 555–558, 2002.
View at: Publisher Site | Google Scholar
A. B. P. Van Kuilenburg, P. Vreken, L. V. A. M. Beex et al., “Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity,” Advances in Experimental Medicine and Biology, vol. 431, pp. 293–298, 1998.
View at: Google Scholar
L. K. Mattison, R. Soong, and R. B. Diasio, “Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics,” Pharmacogenomics, vol. 3, no. 4, pp. 485–492, 2002.
View at: Publisher Site | Google Scholar
R. A. Fleming, G. Milano, A. Thyss et al., “Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients,” Cancer Research, vol. 52, no. 10, pp. 2899–2902, 1992.
View at: Google Scholar
C. Katona, J. Kralovánszky, A. Rosta et al., “Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients,” Oncology, vol. 55, no. 5, pp. 468–474, 1998.
View at: Google Scholar
Z. Lu, R. Zhang, and R. B. Diasio, “Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy,” Cancer Research, vol. 53, no. 22, pp. 5433–5438, 1993.
View at: Google Scholar
M. R. Johnson, J. Yan, L. Shao, N. Albin, and R. B. Diasio, “Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity,” Journal of Chromatography B, vol. 696, no. 2, pp. 183–191, 1997.
View at: Publisher Site | Google Scholar
M. C. Etienne, J. L. Lagrange, O. Dassonville et al., “Population study of dihydropyrimidine dehydrogenase in cancer patients,” Journal of Clinical Oncology, vol. 12, no. 11, pp. 2248–2253, 1994.
View at: Google Scholar
G. Bocci, A. Di Paolo, C. Barbara et al., “Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction,” British Journal of Clinical Pharmacology, vol. 67, no. 1, pp. 132–134, 2009.
View at: Publisher Site | Google Scholar
B. E. Harris, R. Song, S.-J. Soong, and R. B. Diasio, “Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion,” Cancer Research, vol. 50, no. 1, pp. 197–201, 1990.
View at: Google Scholar
A. Di Paolo, R. Danesi, A. Falcone et al., “Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients,” Annals of Oncology, vol. 12, no. 9, pp. 1301–1306, 2001.
View at: Publisher Site | Google Scholar
H. Jiang, J. Lu, and J. Ji, “Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels,” British Journal of Pharmacology, vol. 141, no. 4, pp. 616–623, 2004.
View at: Publisher Site | Google Scholar
S. Sumi, K. Kidouchi, M. Kondou et al., “Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine,” International Journal of Molecular Medicine, vol. 2, no. 4, pp. 477–482, 1998.
View at: Google Scholar
A. H. van Gennip, N. G. Abeling, L. Elzinga-Zoetekouw, L. G. Scholten, A. van Cruchten, and H. D. Bakker, “Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency,” Advances in Experimental Medicine and Biology, vol. 253A, pp. 111–118, 1989.
View at: Google Scholar
J. F. Seitz, J. P. Cano, J. P. Rigault et al., “Chimiothérapie des cancers digestifs étendus par le 5-fluorouracile: relations entre la réponse clinique et la clairance plasmatique du medicament,” Gastroenterologie Clinique et Biologique, vol. 7, no. 4, pp. 374–380, 1983.
View at: Google Scholar
E. C. Gamelin, E. M. Danquechin-Dorval, Y. F. Dumesnil et al., “Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU,” Cancer, vol. 77, no. 3, pp. 441–451, 1996.
View at: Publisher Site | Google Scholar
E. Gamelin, M. Boisdron-Celle, R. Delva et al., “Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1470–1478, 1998.
View at: Google Scholar
M. Ychou, J. Duffour, A. Kramar et al., “Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen,” Cancer Chemotherapy and Pharmacology, vol. 52, no. 4, pp. 282–290, 2003.
View at: Publisher Site | Google Scholar
G. Milano, M. C. Etienne, N. Renée et al., “Relationship between fluorouracil systemic exposure and tumor response and patient survival,” Journal of Clinical Oncology, vol. 12, no. 6, pp. 1291–1295, 1994.
View at: Google Scholar
R. Fety, F. Rolland, M. Barberi-Heyob et al., “Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas,” Clinical Cancer Research, vol. 4, no. 9, pp. 2039–2045, 1998.
View at: Google Scholar
M. Boisdron-Celle, G. Remaud, S. Traore et al., “5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency,” Cancer Letters, vol. 249, no. 2, pp. 271–282, 2007.
View at: Publisher Site | Google Scholar
A. Thyss, G. Milano, N. Renée, J. Vallicioni, M. Schneider, and F. Demard, “Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer,” Cancer Chemotherapy and Pharmacology, vol. 16, no. 1, pp. 64–66, 1986.
View at: Google Scholar
C. J. Van Groeningen, H. M. Pinedo, J. Heddes et al., “Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule,” Cancer Research, vol. 48, no. 23, pp. 6956–6961, 1988.
View at: Google Scholar
D. L. Trump, M. J. Egorin, A. Forrest, J. K. V. Willson, S. Remick, and K. D. Tutsch, “Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole,” Journal of Clinical Oncology, vol. 9, no. 11, pp. 2027–2035, 1991.
View at: Google Scholar
D. I. Jodrell, M. Stewart, R. Aird et al., “5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer,” British Journal of Cancer, vol. 84, no. 5, pp. 600–603, 2001.
View at: Publisher Site | Google Scholar
J. Santini, G. Milano, A. Thyss et al., “5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer,” British Journal of Cancer, vol. 59, no. 2, pp. 287–290, 1989.
View at: Google Scholar
E. E. Vokes, R. Mick, M. S. Kies et al., “Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1663–1671, 1996.
View at: Google Scholar
E. Gamelin, J. Jacob, E. Danquechin-Dorval et al., “Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area,” in Annual Meeting of American Society of Clinical Oncology, Alexandria, Va, USA, 1998, abstract no. 1039.
View at: Google Scholar
A. Di Paolo, M. Lencioni, F. Amatori et al., “5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer,” Clinical Cancer Research, vol. 14, no. 9, pp. 2749–2755, 2008.
View at: Publisher Site | Google Scholar
E. Gamelin, R. Delva, J. Jacob et al., “Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2099–2105, 2008.
View at: Publisher Site | Google Scholar
M. J. Moore, P. Bunting, S. Yuan, and J. J. Thiessen, “Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration,” Therapeutic Drug Monitoring, vol. 15, no. 5, pp. 394–399, 1993.
View at: Google Scholar
A. Di Paolo, R. Danesi, F. Vannozzi et al., “Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer,” Clinical Pharmacology and Therapeutics, vol. 72, no. 6, pp. 627–637, 2002.
View at: Publisher Site | Google Scholar
M. Schneider, M. C. Etienne, G. Milano et al., “Phase II trial of cisplatin, fluorouracil, and pure/folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1656–1662, 1995.
View at: Google Scholar
R.-J. Bensadoun, M.-C. Etienne, O. Dassonville et al., “Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study,” International Journal of Radiation Oncology Biology Physics, vol. 42, no. 2, pp. 237–245, 1998.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2010 Lamya Alnaim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

640

Downloads

0

Citations